Cravens & Co Advisors’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $636K | Buy |
9,210
+177
| +2% | +$12.2K | 0.47% | 38 |
|
|
2025
Q1 | $627K | Buy |
9,033
+1,210
| +15% | +$84K | 0.49% | 37 |
|
|
2024
Q4 | $673K | Sell |
7,823
-274
| -3% | -$23.6K | 0.51% | 38 |
|
|
2024
Q3 | $964K | Buy |
8,097
+128
| +2% | +$15.2K | 0.74% | 31 |
|
|
2024
Q2 | $1.14M | Sell |
7,969
-281
| -3% | -$40.1K | 0.84% | 25 |
|
|
2024
Q1 | $1.06M | Buy |
8,250
+85
| +1% | +$10.9K | 0.88% | 25 |
|
|
2023
Q4 | $845K | Sell |
8,165
-23
| -0.3% | -$2.38K | 0.73% | 31 |
|
|
2023
Q3 | $745K | Buy |
8,188
+72
| +0.9% | +$6.55K | 0.7% | 34 |
|
|
2023
Q2 | $657K | Sell |
8,116
-2,502
| -24% | -$202K | 0.6% | 42 |
|
|
2023
Q1 | $845K | Buy |
10,618
+6
| +0.1% | +$477 | 0.79% | 25 |
|
|
2022
Q4 | $718K | Buy |
+10,612
| New | +$718K | 0.66% | 30 |
|